Arcus Biosciences Ownership | Who Owns Arcus Biosciences?

Overview Forecast RevenueFinancials Chart Transcripts

Arcus Biosciences Ownership Summary

Arcus Biosciences is owned by 47.07% institutional investors, 29.13% insiders, and 23.81% retail investors. Gilead sciences is the largest institutional shareholder, holding 29.26% of RCUS shares. iShares Core S&P Small-Cap ETF is the top mutual fund, with 4.11% of its assets in Arcus Biosciences shares.

RCUS Ownership Benchmark

Type	Name	% Inst	% Insiders	% Retail
Stock	Arcus Biosciences	47.07%	29.13%	23.81%
Sector	Healthcare Stocks	35.58%	11.87%	52.55%
Industry	Biotech Stocks	35.75%	11.83%	52.41%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

Holder	Shares	% Holding	Value
Gilead sciences	31.42M	29.26%	$678.77M
Blackrock funding, inc. /de	15.23M	14.18%	$328.89M
Blackrock	9.76M	11.33%	$148.69M
Vanguard group	7.96M	7.48%	$189.76M
Wellington management group llp	6.09M	5.67%	$131.53M
State street	5.41M	5.04%	$116.92M
Suvretta capital management	5.03M	4.68%	$108.67M
Woodline partners lp	3.78M	3.52%	$81.60M
Marshall wace, llp	3.76M	3.50%	$81.25M
Siren	3.01M	2.80%	$64.95M

Top Institutional Shareholders by % of Total Assets

Holder	Shares	% Assets	Value
Gilead sciences	31.42M	32.05%	$678.77M
Invus financial advisors	1.61M	27.51%	$24.55M
Suvretta capital management	5.03M	2.78%	$108.67M
Parkman healthcare partners	1.21M	2.69%	$26.08M
Dafna capital management	443.83K	2.18%	$9.59M
Siren	3.01M	1.80%	$64.95M
Decheng capital	477.82K	1.56%	$10.32M
Logos global management lp	1.20M	1.29%	$25.92M
Boxer capital	1.60M	1.28%	$24.40M
Knott david m jr	81.24K	1.04%	$1.75M

Top Buyers

Holder	Shares	% Assets	Change
Vanguard group	7.96M	0.00%	1.33M
Citadel advisors	1.33M	0.00%	1.23M
Logos global management lp	1.20M	1.29%	1.20M
Wellington management group llp	6.09M	0.02%	905.01K
State street	5.41M	0.00%	835.93K

Top Sellers

Holder	Shares	% Assets	Change
Point72 asset management	129.27K	0.00%	-3.15M
Toronto dominion bank	-	-	-1.48M
Barclays	74.98K	0.00%	-1.04M
Franklin resources	-	-	-853.49K
Balyasny asset management	-	-	-815.56K

New Positions

Holder	Shares	% Assets	Change	Value
Logos global management lp	1.20M	1.29%	1.20M	$25.92M
Vanguard fiduciary trust	582.92K	0.00%	582.92K	$12.59M
Ensign peak advisors	252.93K	0.01%	252.93K	$5.46M
Vestal point capital, lp	250.00K	0.15%	250.00K	$3.40M
Diadema partners lp	238.14K	0.88%	238.14K	$5.14M

Sold Out

Holder	Change
Dinuzzo private wealth	-1.00
Tortoise investment management	-3.00
Sbi securities	-4.00
Sjs investment consulting	-5.00
Jfs wealth advisors	-7.00

Institutional Ownership Trends

Date	Holdings	Change %	Shares	Change %	Ownership	Change %	Increased Position	Change %	Decreased Position	Change %
Mar 31, 2026	103	-53.81%	50,549,987	-58.37%	47	0.36%	50	-66.22%	28	-22.22%
Dec 31, 2025	136	-30.96%	84,869,998	-15.65%	79	0.89%	89	-11.00%	20	-62.96%
Sep 30, 2025	191	4.37%	99,188,061	2.60%	93	1.13%	96	-4.95%	52	6.12%
Jun 30, 2025	189	-	99,642,989	2.55%	93	0.96%	105	-17.32%	51	70.00%
Mar 31, 2025	187	-3.11%	97,113,724	15.75%	98	1.17%	126	44.83%	30	-55.22%

Top Mutual Funds Shareholders

Holder	Shares	% Holding	Change
iShares Core S&P Small-Cap ETF	5.17M	4.11%	1.18K
Vanguard Health Care Inv	4.12M	3.28%	919.29K
Vanguard Total Stock Mkt Idx Inv	2.83M	2.25%	11.09K
State Street® SPDR® S&P® Biotech ETF	2.41M	1.92%	-23.85K
iShares Russell 2000 ETF	1.98M	1.57%	16.68K
Vanguard US Total Market Shares ETF	1.62M	1.53%	-
SPDR® S&P Biotech ETF	1.20M	1.13%	2.69K
Fidelity Select Health Care	949.76K	0.90%	-
CT (Lux) American Smaller Com 9U USD	906.88K	0.86%	55.03K
Vanguard Small Cap Index	1.01M	0.80%	-4.32K

Recent Insider Transactions

Date	Name	Role	Activity	Value
Jun 01, 2026	Azoy Alexander	Chief Accounting Officer	Sell	$66.02K
May 11, 2026	Goeltz II Robert C.	Chief Financial Officer	Sell	$198.97K
Jan 05, 2026	Jaen Juan C.	President	Sell	$2.32K
Jan 05, 2026	Jaen Juan C.	President	Sell	$633.16K
Jan 05, 2026	Jaen Juan C.	President	Sell	$45.86K

Insider Transactions Trends

Date	Buy	Sell
2026 Q2	-	2
2026 Q1	-	3
2025 Q4	-	31
2025 Q3	-	2
2025 Q2	-	-

RCUS Ownership FAQ

Who Owns Arcus Biosciences?

Arcus Biosciences shareholders are primarily institutional investors at 47.07%, followed by 29.13% insiders and 23.80% retail investors. The average institutional ownership in Arcus Biosciences's industry, Biotech Stocks , is 35.75%, which Arcus Biosciences exceeds.

Who owns the most shares of Arcus Biosciences?

Arcus Biosciences’s largest shareholders are Gilead sciences (31.42M shares, 29.26%), Blackrock funding, inc. /de (15.23M shares, 14.18%), and Blackrock (9.76M shares, 11.33%). Together, they hold 54.76% of Arcus Biosciences’s total shares outstanding.

Does Blackrock own Arcus Biosciences?

Yes, BlackRock owns 11.33% of Arcus Biosciences, totaling 9.76M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 148.69M$. In the last quarter, BlackRock decreased its holdings by -137K shares, a -1.39% change.

Who is Arcus Biosciences’s biggest shareholder by percentage of total assets invested?

Gilead sciences is Arcus Biosciences’s biggest shareholder by percentage of total assets invested, with 32.05% of its assets in 31.42M Arcus Biosciences shares, valued at 678.77M$.

Who is the top mutual fund holder of Arcus Biosciences shares?

iShares Core S&P Small-Cap ETF is the top mutual fund holder of Arcus Biosciences shares, with 4.11% of its total shares outstanding invested in 5.17M Arcus Biosciences shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis

Discover trending investment themes
Find your next best investment
Research stocks using tools